骨密度正常患者的骨折:美国骨科协会Own the Bone注册数据库评估
本研究基于美国骨科协会Own the Bone注册数据库,纳入2016年7月至2021年7月期间≥50岁、发生骨折且具有DXA数据的7219例患者,评估骨密度正常患者的特征。骨密度正常者占8.6%,其中72.9%不结合骨密度计算的FRAX风险升高,12.0%结合骨密度计算的FRAX风险升高;作者认为多数骨密度正常的骨折患者符合抗骨质疏松治疗指征。
要点
- 骨密度正常患者中,不结合骨密度计算的FRAX风险升高者占72.9%,结合骨密度计算者占12.0%。
- 骨密度正常患者中,足踝为最常见的主要骨质疏松性骨折以外的索引骨折部位(13.9%)和既往骨折部位(17.4%)。
- 作者认为,≥50岁成人的次要骨折应被视为前哨事件,需进一步评估。
核心结论
- 多数骨密度正常的骨折患者符合抗骨质疏松治疗指征,包括既往骨折或FRAX风险升高。
- 不结合骨密度计算的FRAX风险较结合骨密度计算者更常升高,提示临床危险因素应与DXA一同考虑。
- 主要骨质疏松性骨折以外的骨折在骨密度正常患者中更常见,作者认为≥50岁成人的次要骨折应被视为前哨事件,需进一步评估。
- 作者认为,除骨密度外其他重要危险因素可能有助于指导进一步的骨骼健康评估。
研究设计与样本
- 研究纳入美国骨科协会Own the Bone(AOA OTB)注册数据库中2016年7月至2021年7月期间发生骨折、≥50岁且有双能X线吸收测定法(DXA)数据的7219例患者。
- 骨密度状态按世界卫生组织T值标准分类,计算骨密度正常患者结合与不结合骨密度的骨折风险评估工具(FRAX)评分。
- 风险升高定义为主要骨质疏松性骨折风险≥20%或髋部骨折风险≥3%。
- 证据等级为预后Level III。
主要发现
- 患者平均年龄70.8±9.71岁,84%为女性,92%为白人。
- 骨密度正常者占8.6%。
- 骨密度正常患者中索引骨折为主要骨质疏松性骨折者占68.6%,骨质疏松患者中占75.6%。
- 骨密度正常患者中,足踝为最常见的主要骨质疏松性骨折以外的索引骨折部位(13.9%)和既往骨折部位(17.4%)。
- 骨密度正常患者中,不结合骨密度计算的FRAX风险升高者占72.9%,结合骨密度计算的FRAX风险升高者占12.0%。
关键数值与推荐
- 风险升高定义为主要骨质疏松性骨折风险≥20%或髋部骨折风险≥3%。
- 骨密度状态按世界卫生组织T值标准分类。
临床怎么用
- 作者认为,临床危险因素应与DXA一同考虑,以识别需要进一步骨骼健康评估的患者。
- 作者认为,≥50岁成人的次要骨折应被视为前哨事件,需进一步评估。
- 作者认为,除骨密度外其他重要危险因素可能有助于指导进一步的骨骼健康评估。
局限性
- 大多数患者为白人,因此可能具有更高的基线骨折风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fractures often occur in patients with normal dual x-ray absorptiometry (DXA)-measured bone mineral density (BMD). DXA does not consider clinical fracture risk factors or bone quality. We hypothesized that patients with normal BMD who sustain a fracture have other characteristics suggesting abnormal bone and an elevated fracture risk requiring additional bone health evaluation and potential anti-osteoporotic treatment. METHODS: A total of 7,219 patients who were ≥50 years of age, had sustained a fracture from July 2016 to July 2021, and had DXA data in the American Orthopaedic Association's Own the Bone (AOA OTB) registry were included in this study. The index and prior fracture site data were obtained. BMD status was classified by the World Health Organization T-score criteria. The Fracture Risk Assessment Tool (FRAX) scores with and without BMD were calculated in patients with normal BMD. An elevated risk was defined as a major osteoporotic fracture risk of ≥20% or a hip fracture risk of ≥3%. RESULTS: The mean patient age (and standard deviation) was 70.8 ± 9.71 years, 84% of patients were female, and 92% of patients were Caucasian. Normal BMD was present in 8.6% of patients. The index fracture was a major osteoporotic fracture in 68.6% of patients with normal BMD and 75.6% of patients with osteoporosis. The most common site for index and prior fractures other than major osteoporotic fractures was the foot and ankle; of patients with normal BMD, 13.9% had this as the most common index site and 17.4% had this as the most common prior site. The FRAX risk calculated without BMD was elevated in 72.9% of patients with normal BMD, and the FRAX risk calculated with BMD was elevated in 12.0% of patients. CONCLUSIONS: Most patients with a fracture and normal BMD met indications, including a prior fracture or elevated FRAX risk, for anti-osteoporotic therapies. Most patients were Caucasian and therefore potentially had a higher baseline fracture risk. The FRAX risk calculated without BMD was elevated more often than the FRAX risk with BMD, implying that clinical risk factors, which highlight multiple opportunities for non-pharmacologic secondary fracture prevention, should be considered along with DXA. Fractures other than major osteoporotic fractures were more common in patients with normal BMD, suggesting that minor fractures in adults who are ≥50 years of age should be considered sentinel events warranting further evaluation. Surgeons must recognize that other important risk factors apart from BMD may help to guide further bone health evaluation. LEVEL OF EVIDENCE: Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.
引用
- Kadri A, Binkley N, Daffner SD, et al. Fracture in Patients with Normal Bone Mineral Density: An Evaluation of the American Orthopaedic Association's Own the Bone Registry. J Bone Joint Surg Am. 2022. PMID: 36575157. doi:10.2106/JBJS.22.00012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。